- Feb 2019 - Feb 2023
- Regina Rabinovich
- Funded by
The world is not on track to achieve the goals proposed by WHO in the Global Technical Strategy for Malaria 2016-2030 (GTS), and currently available tools are unlikely to suffice. Vector control, our most effective strategy, is now doubly threatened by widespread insecticide resistance and residual transmission caused by mosquito behavioral adaptations that allow them to elude home-based vector control tools such as treated bed nets and indoor residual spraying.
Ivermectin is an antiparasitic drug distributed to more than 2.5 billion people over the last 30 years in mass drug administration campaigns to directly treat two Neglected Tropical Diseases (NTDs). More recently, it has been noted that ivermectin can also increase the mortality of mosquitoes that feed on treated humans or animals during a time period that can be up to 28 days, depending on the dose.
Thus, Mass Drug Administration (MDA) of ivermectin to humans and/or livestock holds potential to complement the malaria toolbox by tackling residual transmission and help the malaria community get back on track to achieve the GTS goals.
BOHEMIA will evaluate the MDA of ivermectin to humans and/or livestock in two African countries -Tanzania and Mozambique- during the malaria season, and will collect data on the epidemiological impact to support normative guidance, global and national policy change.
Should evidence be supportive, engagement with WHO and other key stakeholders will support the conditions for a policy recommendation, and subsequent national adoption.
BOHEMIA combines evidence generation and stakeholder engagement to enable the path for policy and implementation of ivermectin as a new vector control tool complementary to standard tools (treated bed nets and indoor residual spraying).
The BOHEMIAconsortium is led by ISGlobal and includes:
- Centro de Investigaçao em Saúde de Manhiça
- Ifakara Health Institute
- University Hospital Bern
- University of Oxford
- Virginia Tech
25.3 U$ million (awarded by Unitaid)
- Nelly Regina Rabinovich Director of the Malaria Elimination Initiative
- Carlos Javier Chaccour
- Mary-Ann Richardson BOHEMIA Clinical Trial Manager
- Paula Ruiz-Castillo Postdoctoral Fellow
- Júlia Montaña Lopez
- Patricia Nicolás Predoctoral Fellow
- Paulo Cunha
- Mary Mael Project Assistant
- Beatriz Fiestas Communications Coordinator
- Sonia Tomás Falco
Other projectsSee Past Projects
The Malaria Eradication Scientific Alliance - MESA is dedicated to advancing the science of malaria eradication.
Study of immune correlates of protection against malaria after vaccination with RTS,S/AS01E: a comprehensive immunological arm of a Phase III double-blind, randomized, controlled multi-center trial
Mozambican Alliance Towards Elimination of Malaria
Pregnant women as a sentinel group for malaria surveillance in an era of changing malaria transmission
A path towards new diagnostic and prevention tools for severe infectious pathologies
Exploration of the singularities of the sugar nucleotide metabolism and description of novel glycosylation pathways in the malaria parasite
Investigating new aspects of the mechanisms and biological functions of epigenetic variation in malaria parasites
Mechanistic aspects of anemia and splenomegaly caused by plasmodium vivax, a neglected human parasite
Transforming IPT for optimal pregnancy
Development of nanovectors for the targeted delivery in Anopheles mosquitoes of agents blocking transmission of Plasmodium parasites
Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults
P. falciparum genomic intelligence in Mozambique
Malaria mass and focal drug administration to advance malaria elimination in Mozambique: accelerating programmatic implementation and policy translation
MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention
Enhanced and equitable coverage of COVID-19 testing and treatment in Bolivia and Paraguay